Regeneron Pharmaceuticals (REGN) Non-Current Deffered Revenue (2009 - 2026)

Regeneron Pharmaceuticals' Non-Current Deffered Revenue history runs 18 years deep, the most recent figure standing at $225.1 million for Q1 2026.

• On a quarterly basis, Non-Current Deffered Revenue rose 6.28% year-over-year to $225.1 million in Q1 2026; TTM through Mar 2026 was $225.1 million, a 6.28% increase from a year earlier, with the FY2025 full-year figure at $208.7 million, up 12.39% from the prior year.
• Non-Current Deffered Revenue grew to $225.1 million in Q1 2026 per REGN's latest filing, from $208.7 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $225.1 million in Q1 2026 and bottomed at $33.5 million in Q1 2022.
• The 5-year median for Non-Current Deffered Revenue is $185.7 million (2024), against an average of $148.9 million.
• Across the five-year window, Non-Current Deffered Revenue fell 4.77% in 2022 and soared 155.22% in 2023, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $69.8 million in 2022, then jumped by 81.52% to $126.7 million in 2023, then soared by 46.57% to $185.7 million in 2024, then increased by 12.39% to $208.7 million in 2025, then rose by 7.86% to $225.1 million in 2026.
• Per Business Quant, the three latest REGN Non-Current Deffered Revenue figures stand at $225.1 million (Q1 2026), $208.7 million (Q4 2025), and $219.2 million (Q3 2025).